Upifitamab

Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC) . Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) [1].

Product Specifications

CAS Number

[2254118-43-7]

Product Name Alternative

XMT-1535

UNSPSC

12352203

Target

ADC Antibody

Type

Inhibitory Antibodies

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/upifitamab.html

Purity

Solubility

10 mM in DMSO

Smiles

[Upifitamab]

Molecular Weight

(145.06 kDa)

References & Citations

[1]Theresa L. Werner, et al., 32 UPGRADE: phase 1 combination trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer, Gynecologic Oncology Reports, Volume 44, Supplement 2, 2022, Page S16, ISSN 2352-5789.